Atara Biotherapeutics (0HIY.L) Stock Price

$7.68 0%

Sign up
to add to portfolio

AI Score

Sell
  • Alternative

    4
  • Fundamental

    1
  • Technical

    3

Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.

Sign up to get access to more historical data and insights on Atara Biotherapeutics, AI stock picks, stock alerts and much more.

Sign up

0HIY.L AI Stock Analysis

AI stock analysis for 0HIY.L is missing at the moment.

Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Atara Biotherapeutics (0HIY.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.

Sign up and become a member to get access to AI stock analysis.

Sign up

Atara Biotherapeutics (0HIY.L) Price Prediction

Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Atara Biotherapeutics (0HIY.L), currently trading at $7.68, will... Sign up to access price prediction.

Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.

About 0HIY.L

LSE
  • Atara Biotherapeutics, Inc.

  • Symbol

    0HIY.L

  • Market

    LSE

  • Industry

    Medical - Pharmaceuticals

  • Market Cap

    54.5M

0HIY.L Alternative Data

Web Traffic

Atara Biotherapeutics receives an estimated 6780 monthly visitors to atarabio.com.

  • Web Traffic

    6780

  • Change from Previous Month

    21.1%

  • 3 Month Change

    35.6%

  • YoY Change

    35.6%

Twitter Followers

Atara Biotherapeutics has 2,079 Twitter Followers on its main Twitter (also known as X) account.

  • Twitter Followers

    2079

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0.3%

Job Postings

Atara Biotherapeutics currenly has an estimated 0 open job postings.

  • Job Postings

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

Reddit Mentions

Atara Biotherapeutics has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.

  • Reddit Mentions

    0

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

LinkedIn Followers

37,915 are following Atara Biotherapeutics on LinkedIn, up by 0.2% over the last month.

  • LinkedIn Followers

    37915

  • Daily Change

    0.2%

  • 1 Month Change

    0.2%

  • 3 Month Change

    0.7%

LinkedIn Employees

According to LinkedIn, Atara Biotherapeutics has 188 employees, down by -6.9% over the last month.

  • LinkedIn Employees

    188

  • Daily Change

    6.9%

  • 1 Month Change

    6.9%

  • 3 Month Change

    27.1%

Business Outlook

According to employee reviews, the business outlook among employees at Atara Biotherapeutics is 40 out of 100 (bearish).

  • Business Outlook

    40

  • Change from Previous Month

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

News Mentions

Atara Biotherapeutics was mentioned 1 times in the news yesterday.

  • News Mentions

    1

  • Daily Change

    0%

  • 1 Month Change

    0%

  • 3 Month Change

    0%

  • YoY Change

    0%

0HIY.L Financials

0HIY.L Key Metrics
  • Total Revenue

    $32.8M

  • Net Income

    -$12.7M

  • Earnings per Share

    -$1.19

  • Free cash flow

    -$24.6M

  • EBITDA

    -$10.6M

  • EBITDA Ratio

    -0.323482

  • Total Assets

    $62M

0HIY.L 2-year Revenue & Income
0HIY.L 2-year Free Cash Flow

0HIY.L Technicals

0HIY.L SMA
0HIY.L RSI

FAQ

What's the current price of Atara Biotherapeutics (0HIY.L) Stock?
The price of an Atara Biotherapeutics (0HIY.L) share is $7.68.

What's the market cap of Atara Biotherapeutics?
The current market cap of Atara Biotherapeutics is 54.5M.

Should I buy or sell 0HIY.L?
Atara Biotherapeutics exhibits several negative alternative data signals, leading us to expect continued underperformance in the coming months. As a result, we maintain a negative outlook on this stock.

Is Atara Biotherapeutics a good investment?
Considering the fundamentals, technical analysis, and alternative data insights, it may not be the best time to invest in Atara Biotherapeutics stock. There are several bearish signals and market challenges that could negatively impact Atara Biotherapeutics' future performance, suggesting that caution should be exercised before making any investment decisions.

Is now a good time to buy Atara Biotherapeutics (0HIY.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it may not be the best time to buy Atara Biotherapeutics stock right now, as the outlook appears bearish.

What are some stocks similar to Atara Biotherapeutics (0HIY.L) that investors often compare it to?
Atara Biotherapeutics (0HIY.L) is often compared to similar stocks such as Vertex Pharmaceuticals Incorporated, Neurocrine Biosciences, Emergent BioSolutions Inc., Abeona Therapeutics Inc. and Walgreens Boots Alliance.

What is the forecast for Atara Biotherapeutics' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Atara Biotherapeutics' stock price to be around $7.18 in 2026. Starting from the current price of $7.68, this represents a 6.4% change in price, indicating a bearish outlook for the stock.

How to buy Atara Biotherapeutics (0HIY.L) Stock?
Atara Biotherapeutics stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Atara Biotherapeutics shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.